HeraMED Ltd

As of December 31, 2025, HeraMED Ltd carries a market capitalization of 38.53M, placing it among publicly traded companies globally. Its enterprise value stands at 37.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, HeraMED Ltd has 1.07B shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 131.32, and the price-to-book ratio stands at 41.38.

These figures are as of December 31, 2025. The EV/Sales ratio of 127.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 37.44M versus a market cap of 38.53M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, HeraMED Ltd maintains a current ratio of 4.49, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.33, indicating elevated leverage, while an interest coverage ratio of -1,061.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, HeraMED Ltd posted a negative return on equity (ROE) of -223.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -138.29, reflecting losses generated across the asset base. The company generates approximately 17.26 in revenue per employee across its workforce of 17,000.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, HeraMED Ltd's stock has gained approximately 16.13% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.04.

Over the twelve months ended December 31, 2025, HeraMED Ltd generated 293,380.00 in revenue and converted that into -4.13M in net income, yielding earnings per share of 0.00. EBITDA reached -4.47M, while operating income came in at -3.60M.

As of December 31, 2025, HeraMED Ltd holds 1.37M in cash and equivalents against 282,386.00 in total debt, resulting in a net debt position of -1.09M. Total book value stands at 931,029.00, with working capital of 1.13M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025. The operating margin of -1,228.15 and net profit margin of -1,408.29 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -4.96, meaning HeraMED Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HeraMED Ltd's most recent stock split took place on January 23, 2024 with a 45:46 split ratio.

As of December 31, 2025, HeraMED Ltd has an Altman Z-Score of -7.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.